Vertex Pharmaceuticals INC / Ma Form 4 insider transactions

Bruce I. Sachs, a director of Vertex Pharmaceuticals, acquired deferred stock units representing 111.654 shares of common stock on January 15, 2025.

David Altshuler, EVP and Chief Scientific Officer at Vertex Pharmaceuticals, sold 15 shares of common stock at $478.56 per share under a pre-arranged trading plan.

Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, sold 3,000 shares of common stock at $518.27 per share under a pre-arranged trading plan.

Reshma Kewalramani, CEO of Vertex Pharmaceuticals, sold 15,198 shares of common stock at a price of $515 per share on November 8, 2024, according to a recent SEC Form 4 filing.

Director Bruce Sachs acquired deferred stock units convertible to 90.32 shares of Vertex Pharmaceuticals common stock.

EVP and Chief Legal Officer of Vertex Pharmaceuticals, Jonathan Biller, reports the disposition of shares under a pre-arranged trading plan.

Jeffrey Leiden, Executive Chairman of Vertex Pharmaceuticals, sold 3,784 shares of common stock at $499 per share on August 30, 2024, under a pre-arranged 10b5-1 trading plan.

Director Sangeeta N. Bhatia reported the acquisition and disposal of Vertex Pharmaceuticals (VRTX) common stock on August 30, 2024, according to a Form 4 filing with the SEC.

Director Sangeeta N. Bhatia of Vertex Pharmaceuticals exercised stock options and sold shares on August 8, 2024, according to a Form 4 filing with the SEC.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reported selling 2,280 shares of common stock at a price of $476.75 on August 7, 2024, according to a Form 4 filing with the SEC.

Director Bruce Sachs exercised stock options and sold shares of Vertex Pharmaceuticals under a pre-arranged trading plan.

Vertex Pharmaceuticals CEO Reshma Kewalramani sold 15,202 shares of common stock at $505 per share on July 30, 2024, under a pre-arranged 10b5-1 trading plan.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, sold 2,280 shares of common stock on July 24, 2024, at a price of $488.46 per share.

Vertex Pharmaceuticals CEO Reshma Kewalramani sold 15,202 shares of common stock at $497 per share on July 22, 2024, according to a Form 4 filing.

Director Bruce Sachs acquired deferred stock units convertible to common stock in Vertex Pharmaceuticals.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, sold 2,280 shares of common stock at a price of $487.34 per share on July 10, 2024, according to a Form 4 filing.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, sold 2,280 shares of common stock on June 26, 2024, at a price of $471.72 per share, according to a Form 4 filing.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reported the sale of 2,280 shares of common stock on June 12, 2024, at a price of $478 per share.

Edward Morrow Atkinson III, EVP and Chief Technical Operations Officer of Vertex Pharmaceuticals, sold shares of common stock under a pre-arranged 10b5-1 trading plan.

EVP, Chief Patient & External Affairs Officer of Vertex Pharmaceuticals, Amit Sachdev, reports changes in beneficial ownership of company stock.

Charles Wagner, EVP & Chief Financial Officer of Vertex Pharmaceuticals, sold 3,250 shares of common stock at $460 per share on June 3, 2024, under a pre-arranged trading plan.

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, sold 2,175 shares of common stock at $460 per share on June 3, 2024, under a pre-arranged 10b5-1 trading plan.

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, sold shares of common stock under a pre-arranged trading plan.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, sold 2,280 shares of common stock at a price of $445.56 on May 29, 2024, according to a recent SEC filing.

Charles Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, sold 3,250 shares of common stock at $454.79 per share on May 28, 2024, under a pre-arranged trading plan.

Reshma Kewalramani, CEO of Vertex Pharmaceuticals, reports the acquisition and disposal of company stock on May 24, 2024, according to a pre-arranged trading plan.

Director Bruce Sachs exercised stock options and sold shares of Vertex Pharmaceuticals (VRTX) on May 22, 2024, under a pre-arranged trading plan.

Reshma Kewalramani, CEO of Vertex Pharmaceuticals, sold 15,202 shares of common stock at $447 per share on May 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Amit Sachdev, EVP Chief Patient & External Affairs Officer at Vertex Pharmaceuticals, reports selling 32 shares of common stock at $430.93 per share.

Stuart Arbuckle, EVP and COO of Vertex Pharmaceuticals, reports the sale of 69 shares of common stock at a price of $430.93 per share.